Corvus Pharmaceuticals Inc (CRVS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $897.52M
Last updated: Nov 17, 2026 at 11:05 AM ET
Corvus Pharmaceuticals Inc (CRVS) Stock Forecast
Analysts expect Corvus Pharmaceuticals (CRVS) to earn -$0.80 per share in the fiscal year ending Dec 31, 2026. Of 7 analysts, 7 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 3 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 7 ratings average 1.86, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 14.3% |
| Buy | 6 | 85.7% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 7
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss.
- Fiscal year ending Dec 31, 2026
- -$0.80
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$1.10
- EPS consensus, revenue $2.10M
- Next report
- Mar 10, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.80 | -$0.81 to -$0.79 | 4 | N/A | N/A | 5 |
| Dec 31, 2027 | -$1.10 | -$1.31 to -$0.87 | 4 | $2.10M | N/A | 3 |
Quarterly Estimates
The EPS consensus falls from -$0.24 for the quarter ending Dec 31, 2026 to -$0.27 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.24 | -$0.28 to -$0.19 | 9 |
| Mar 31, 2027 | -$0.27 | -$0.29 to -$0.25 | 3 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 0 upward and 7 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 3 |
| Fiscal year ending Dec 31, 2027 | 0 | 3 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.78.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.80 | -$0.78 | -$0.78 | -$0.78 | -$0.78 | N/A |
| Fiscal year ending Dec 31, 2027 | -$1.10 | -$1.07 | -$1.07 | -$1.07 | -$1.08 | N/A |
| Quarter ending Mar 31, 2027 | -$0.27 | -$0.26 | -$0.26 | -$0.26 | -$0.26 | N/A |
Frequently Asked Questions About CRVS
What is the CRVS stock forecast?
Consensus analyst estimates put Corvus Pharmaceuticals's EPS at -$0.80 for the fiscal year ending Dec 31, 2026. The consensus rating from 7 analysts is Buy.
How do analysts rate CRVS stock?
Of 7 analysts covering Corvus Pharmaceuticals, 1 rates it Strong Buy, 6 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from CRVS next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.80, with estimates from -$0.81 to -$0.79 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.10, with estimates from -$1.31 to -$0.87 from 4 analysts.
What revenue do analysts expect from Corvus Pharmaceuticals next year?
For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $2.10M.
How many analysts cover CRVS?
7 analysts rate Corvus Pharmaceuticals stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
CRVS pages: Overview, Earnings, Forecast, Financials, Competitors